InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's DiseaseOctober 24, 2024 8:00 AM EDT | Source: InMed PharmaceuticalsVancouver, British Columbia--(Newsfile Corp. - October 24, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it will be participating in the upcoming Fierce ...

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory BoardOctober 22, 2024 8:00 AM EDT | Source: InMed PharmaceuticalsVancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Dr. Ba ...

Core Viewpoint - InMed Pharmaceuticals reported a financial update for fiscal year 2024, highlighting advancements in its drug development pipeline, particularly for Alzheimer's disease and dry Age-related Macular Degeneration (AMD), alongside a revenue increase for its subsidiary, BayMedica [2][4]. Financial Performance - The company generated $4.6 million in revenues for fiscal year 2024, marking an 11% increase compared to the previous fiscal year [2][10]. - For the year ending June 30, 2024, InMed recorded a net loss of $7.7 million, a slight improvement from a net loss of $7.9 million in the prior year [4][11]. - Cash, cash equivalents, and short-term investments totaled $6.6 million as of June 30, 2024 [4][14]. Drug Development Programs INM-901 - INM-901 is a proprietary small molecule drug candidate targeting multiple biological pathways associated with Alzheimer's disease, showing neuroprotective effects and potential for cognitive function improvement [5][6]. - The program has advanced significantly, with ongoing preclinical studies demonstrating its ability to reduce neuroinflammation and improve neuronal function [5][6]. - The drug can be administered orally, achieving therapeutic levels comparable to intraperitoneal injection, which may offer advantages over current treatments [5]. INM-089 - INM-089 is being developed for the treatment of dry AMD, with preclinical data indicating enhanced neuroprotection of photoreceptors and improved retinal pigment epithelium integrity [6][7]. - The data suggests INM-089 may be particularly effective for geographic atrophy, a more advanced stage of dry AMD [7]. INM-755 - The INM-755 program is focused on dermatological applications, with potential expansion beyond Epidermolysis bullosa (EB) to address chronic, severe itch [8]. Intellectual Property - InMed has strengthened its patent portfolio with the issuance of three new U.S. patents related to formulation, manufacturing processes, and drug delivery [4][9]. BayMedica Subsidiary - BayMedica, the company's commercial subsidiary, achieved $4.6 million in sales for fiscal year 2024, reflecting an 11% increase from the previous year [10][13].

Core Insights - InMed Pharmaceuticals has strengthened its patent portfolio with the issuance of three U.S. patents, enhancing its intellectual property protection for drug candidates targeting high unmet medical needs [2][3]. Patent Portfolio Summary - The company now holds a total of 13 patent families covering new chemical entities, formulations, manufacturing methods, and methods of use [4]. - The newly granted patents include: - A method of use patent for topical cannabinoid formulations in treating epidermolysis bullosa, granted in the U.S., Australia, Japan, and Israel, with pending status in several other jurisdictions [3][4]. - A biosynthesis patent for manufacturing proprietary cannabinoid analogs, granted in the U.S. [3][4]. - An ocular drug delivery formulation patent, granted/allowed in the U.S., Europe, Australia, Japan, and India, with pending status in other jurisdictions [3][4]. Company Focus and Future Plans - InMed is committed to expanding its patent portfolio to protect its novel drug candidates and manufacturing methods, particularly for its INM-901 program targeting Alzheimer's disease and INM-089 for dry Age-related Macular Degeneration [4][5].

Core Insights - InMed Pharmaceuticals Inc. has confirmed INM-901 as an oral formulation for its Alzheimer's disease development programs [1] - Recent preclinical studies show that INM-901 can achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal injection [2][3] - The oral formulation of INM-901 maintains similar drug exposure levels in the brain over a 24-hour period as compared to IP delivery [3] Company Developments - Michael Woudenberg, COO of InMed, expressed excitement over the data confirming that INM-901 can cross the blood-brain barrier as an oral formulation, highlighting its advantages for Alzheimer's treatment [4] - The company is conducting further studies on drug metabolism, dose-ranging, and pharmacokinetics to support an IND submission [6] Market Reaction - Following the announcement, INM stock experienced a significant increase of 241.8%, reaching $0.51 [6]

. . July 30, 2024 8:00 AM EDT | Source: InMed Pharmaceuticals Vancouver, British Columbia--(Newsfile Corp. - July 30, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced positive results from initial data sets from a long-term (7 months of dosing) in vivo preclinical Alzheimer's Disease ("AD") study of INM-901 which confi ...

. . ● . InMed to Present at the Emerging Growth Conference June 10, 2024 5:18 PM EDT | Source: InMed Pharmaceuticals Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, today announced the Company will be presenting at the upcoming Emerging Growth Conference scheduled for June 12-13, 2024. InMed's CEO, Mr. Eri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 98- ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada ...